According to filings with the U.S. Securities and Exchange Commission, Dualitas Therapeutics, Inc. is raising up to $66,599,990.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Dualitas Therapeutics, Inc.
Dualitas (pronunciation: doo-AWL-ih-tahs) was founded in 2023 by a team of world-class biotherapeutic engineers and drug developers to fundamentally transform how differentiated bispecific antibody (BsAb) therapies are discovered. Unlike traditional typically narrow approaches to bispecific discovery, our proprietary DualScreen Bispecific Discovery Engine operates at combinatorial scale to enable discovery of unexplored co-target combinations and novel cell-surface proximity biology, delivering bispecific candidates with highly differentiated activity. Our portfolio, built from DualScreen, includes lead programs DTX-102 in autoimmune disease and DTX-103 in allergic disease. Each candidate has demonstrated differentiated preclinical profiles when benchmarked to available therapies. Existing BsAb discovery approaches narrowly focus on pre-determined target pairs of known biology. In contrast, DualScreen functionally screens cell surfaceomes the entire cell surface across a vast range of targets and epitopes to identify BsAb combinations that are truly synergistic rather than simply additive. Up to 100,000+ unique bispecific combinations can be arrayed and screened in high throughput functional assays to identify BsAbs and co-targets with synergistic activities unachievable by conventional therapeutics. DualScreen discovers powerful cell surface proximity mechanisms and rapidly delivers BsAbs with differentiated pharmacology. DualScreen has discovered an expanding collection of novel cell-surface proximity engagers reusable antibody arms that can be plugged into a wide range of BsAbs to elicit repeatable proximity mechanisms. Dualitas engagers can be paired with antibody arms to diverse disease-relevant immune targets to impart differentiated pharmacology that monospecific agents cannot achieve. Dualitas two lead programs utilize Engager E1 to bring substantial differentiation to validated therapeutic pathways.

To learn more about Dualitas Therapeutics, Inc., visit https://www.dualitastx.com/
Dualitas Therapeutics, Inc. Linkedin Page: https://www.linkedin.com/company/dualitas-therapeutics/

Contact:
Richard Murray, President
917-640-1086

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.